These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37686510)

  • 1. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
    Tamura Y; Ono A; Nakahara H; Hayes CN; Fujii Y; Zhang P; Yamauchi M; Uchikawa S; Teraoka Y; Uchida T; Fujino H; Nakahara T; Murakami E; Tsuge M; Serikawa M; Miki D; Kawaoka T; Okamoto W; Imamura M; Nakamura Y; Awai K; Kobayashi T; Ohdan H; Fujita M; Nakagawa H; Chayama K; Aikata H; Oka S
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.
    Sasaki R; Nagata K; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Soyama A; Hidaka M; Eguchi S; Shigeno M; Yamashima M; Yamamichi S; Ichikawa T; Kugiyama Y; Yatsuhashi H; Nakao K
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI.
    Kubo A; Suda G; Kimura M; Maehara O; Tokuchi Y; Kitagataya T; Ohara M; Yamada R; Shigesawa T; Suzuki K; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Sakamoto N
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI.
    Kuwano A; Tanaka K; Yada M; Nagasawa S; Morita Y; Masumoto A; Motomura K
    Mol Clin Oncol; 2022 Feb; 16(2):53. PubMed ID: 35070302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor steatosis and glutamine synthetase expression in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
    Kurebayashi Y; Tsujikawa H; Sugimoto K; Yunaiyama D; Araki Y; Saito K; Takahashi H; Kakegawa T; Wada T; Tomita Y; Abe M; Yoshimasu Y; Takeuchi H; Hirata T; Sakamaki K; Kakimi K; Nagao T; Itoi T; Sakamoto M
    Hepatol Res; 2023 Oct; 53(10):1008-1020. PubMed ID: 37300323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI.
    Ohama H; Imai Y; Nakashima O; Kogita S; Takamura M; Hori M; Seki Y; Sawai Y; Igura T; Fukuda K; Makino Y; Morimoto O; Ohsawa M; Sakamoto M; Murakami T
    J Gastroenterol; 2014 Jun; 49(6):1081-93. PubMed ID: 23903870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
    Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
    Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
    Eso Y; Takeda H; Taura K; Takai A; Takahashi K; Seno H
    Curr Oncol; 2021 Oct; 28(5):4157-4166. PubMed ID: 34677270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
    Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
    JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.
    Inoue T; Kudo M; Komuta M; Hayaishi S; Ueda T; Takita M; Kitai S; Hatanaka K; Yada N; Hagiwara S; Chung H; Sakurai T; Ueshima K; Sakamoto M; Maenishi O; Hyodo T; Okada M; Kumano S; Murakami T
    J Gastroenterol; 2012 Sep; 47(9):1036-47. PubMed ID: 22526270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.
    Galia M; Agnello F; Sparacia G; Matranga D; Albano D; Midiri M; Lagalla R
    Radiol Med; 2018 Jul; 123(7):489-497. PubMed ID: 29546493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
    Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.
    Aoki T; Nishida N; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Yamada A; Sofue K; Tsurusaki M; Kudo M
    Liver Cancer; 2021 Nov; 10(6):615-628. PubMed ID: 34950184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma.
    Tokunaga T; Tateyama M; Kondo Y; Miuma S; Miyase S; Tanaka K; Narahara S; Inada H; Kurano S; Yoshimaru Y; Nagaoka K; Watanabe T; Setoyama H; Fukubayashi K; Tanaka M; Tanaka Y
    Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
    Chiang CL; Chan SK; Lee SF; Choi HC
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.
    Chou YC; Lao IH; Hsieh PL; Su YY; Mak CW; Sun DP; Sheu MJ; Kuo HT; Chen TJ; Ho CH; Kuo YT
    World J Gastroenterol; 2019 Jun; 25(21):2636-2649. PubMed ID: 31210715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl-Diethylenetriaminepentaacetic Acid MRI.
    Kunichika H; Minamiguchi K; Tachiiri T; Shimizu K; Taiji R; Yamada A; Nakano R; Irizato M; Yamauchi S; Marugami A; Marugami N; Kishida H; Nakagawa H; Takewa M; Kageyama K; Yamamoto A; Ueshima E; Sofue K; Kita R; Kurakami H; Tanaka T
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.